Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Rondell Patrell Graham

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8686-4867; OpenAlex author ID A5003662598, A5046724542, A5135219643. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
106
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 5 papers · 2023: 3 papers · 2024: none · 2025: 2 papers · 2026: 3 papers

Papers 22

  1. Real world clinical characteristics of Claudin 18.2 expression in patients with pancreatic adenocarcinoma. Last author DOI 10.1007/s00428-026-04544-9↗
  2. Anatomically constrained deep learning for clinical-grade volumetric pancreatic cancer segmentation: development, validation, and architectural benchmarking. Co-author DOI 10.1038/s41698-026-01587-8↗
  3. KDM6 Histone Demethylases Tune Pancreatic Cancer Plasticity. Co-author DOI 10.1158/0008-5472.can-25-3126↗
  4. Genomic and Immune Landscape of Pancreatic Ductal Adenocarcinoma Associated with Germline Pathogenic Variants in ATM. Co-author DOI 10.1158/1078-0432.ccr-24-4120↗
  5. Emerin is an effector of oncogenic KRAS-driven nuclear dynamics in pancreatic cancer. Co-author DOI 10.1172/jci.insight.187799↗
  6. Long-Term Outcomes and Risk of Pancreatic Cancer in Intraductal Papillary Mucinous Neoplasms. Co-author DOI 10.1001/jamanetworkopen.2023.37799↗
  7. Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2022-328154↗
  8. Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-22-0916↗
  9. Pancreatic Cancer is More Frequently Early Stage at Diagnosis in Surgically Resected Intraductal Papillary Mucinous Neoplasms With Preoperative Surveillance. Co-author DOI 10.1016/j.gastha.2022.07.004↗
  10. Tissue methylated DNA markers for sporadic pancreatic cancer are strongly associated with familial and genetically predisposed pancreatic cancer. Co-author DOI 10.1016/j.pan.2022.06.259↗
  11. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Socie… Co-author DOI 10.1097/pas.0000000000001853↗
  12. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10991-2↗
  13. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7041↗
  14. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003284↗
  15. Tyrosine Phosphoproteomics of Patient-Derived Xenografts Reveals Ephrin Type-B Receptor 4 Tyrosine Kinase as a Therapeutic Target in Pancreatic Cancer. Co-author DOI 10.3390/cancers13143404↗
  16. Endoscopic ultrasound may be used to deliver gene expression signatures using digital mRNA detection methods to immunophenotype pancreatic ductal adenocarcinom… Co-author DOI 10.1016/j.pan.2019.12.002↗
  17. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Co-author DOI 10.1016/j.pan.2020.06.015↗
  18. Successful Secondary Engraftment of Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma Patient-Derived Xenografts After Previous Failed Primary Engraftmen… Co-author DOI 10.1016/j.tranon.2018.09.008↗
  19. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient st… Co-author DOI 10.18632/oncotarget.9440↗
  20. Clinical characteristics and overall survival in patients with anaplastic pancreatic cancer. Co-author DOI 10.1177/000313481408000218↗
  21. Rare ALK expression but no ALK rearrangement in pancreatic ductal adenocarcinoma and neuroendocrine tumors. Co-author DOI 10.1097/mpa.0b013e3182847bd0↗
  22. Clinical outcomes for anaplastic pancreatic cancer: a population-based study. First author DOI 10.1016/j.jamcollsurg.2012.06.418↗

Closest collaborators

The 25 strongest of 106 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mark Joseph Truty · 8 shared papers, 2019–2023 · strength 0.95
  2. Shounak Majumder · 5 shared papers, 2022–2026 · strength 0.91
  3. Robert R. McWilliams · 4 shared papers, 2021–2025 · strength 0.55
  4. Suresh T. Chari · 3 shared papers, 2022–2026 · strength 0.54
  5. Amro M. Abdelrahman · 4 shared papers, 2022–2023 · strength 0.51
  6. Jennifer A. Yonkus · 4 shared papers, 2022–2023 · strength 0.51
  7. Roberto Alva‐Ruiz · 4 shared papers, 2022–2023 · strength 0.51
  8. Ajit Harishkumar Goenka · 3 shared papers, 2021–2026 · strength 0.50
  9. Sean Patrick Cleary · 4 shared papers, 2021–2022 · strength 0.48
  10. Michael L. Kendrick · 4 shared papers, 2021–2022 · strength 0.48
  11. David W. Dawson · 2 shared papers, 2025–2026 · strength 0.39
  12. Thorvardur Ragnar Halfdanarson · 3 shared papers, 2021–2022 · strength 0.36
  13. Christopher Leigh Hallemeier · 3 shared papers, 2021–2022 · strength 0.36
  14. Lizhi Zhang · 4 shared papers, 2013–2022 · strength 0.35
  15. Fergus Joseph Couch · 2 shared papers, 2022–2025 · strength 0.34
  16. Grace Kim · 2 shared papers, 2022–2026 · strength 0.32
  17. Claudio Luchini · 2 shared papers, 2022–2026 · strength 0.32
  18. Allison L. Kerper · 1 shared paper, 2026 · strength 0.30
  19. Ferga C. Gleeson · 3 shared papers, 2016–2022 · strength 0.29
  20. Michael J. Levy · 3 shared papers, 2016–2022 · strength 0.29
  21. Ryan Michael Carr · 2 shared papers, 2020–2025 · strength 0.28
  22. Martín E. Fernández-Zapico · 2 shared papers, 2020–2025 · strength 0.28
  23. Jaime de la Fuente · 2 shared papers, 2022–2023 · strength 0.27
  24. Arjun Chatterjee · 2 shared papers, 2022–2023 · strength 0.27
  25. Santhi Swaroop Vege · 2 shared papers, 2022–2023 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.